Seramorelin Acetate | 10 vials
Sermorelin acetate is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically consisting of the first 29 amino acids of the endogenous 44-amino acid hormone . It is considered the shortest fully functional fragment of GHRH, capable of stimulating the pituitary gland to release growth hormone (GH) .
Key Specifications:
| Property | Specification |
|---|---|
| CAS Number | 114466-38-5 |
| UNII | 00IBG87IQW |
| Molecular Formula | C₁₄₉H₂₄₆N₄₄O₄₂S (free base) |
| Molecular Weight | ~3,358 Da (free base) |
| Synonyms | Geref, Gerel, GHRH (1-29), Growth hormone-releasing factor (1-29) |
| Amino Acid Sequence | YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH₂ |
| Purity (Research Grade) | ≥98% |
| Appearance | Lyophilized powder |
| Storage | Store at -20°C for long-term; 0-4°C for short-term |
| Solubility | Soluble in DMSO |
Mechanism of Action:
Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone (GH) . This triggers a cascade of physiological effects:
| Effect | Description |
|---|---|
| GH secretion | Stimulates pituitary GH release in a pulsatile pattern mirroring natural physiology |
| IGF-1 elevation | GH stimulates hepatic IGF-1 production, mediating many anabolic effects |
| Preserved feedback | IGF-1 and somatostatin feedback loops keep GH within physiologic ranges |
| Short half-life | 11-12 minutes, supporting physiologic pulses rather than continuous stimulation |
Key Research Applications:
| Category | Applications |
|---|---|
| Growth Hormone Research | GH secretion studies, somatotroph function, GH deficiency models |
| Anti-Aging Research | Age-related GH decline, body composition, skin thickness, vitality |
| Muscle & Recovery | Lean body mass, protein synthesis, muscle preservation |
| Metabolic Research | Body composition, lipid metabolism, insulin sensitivity |
| Cardiovascular Research | Cardiac remodeling post-myocardial infarction, angiogenesis |
Clinical Status:
Sermorelin acetate was FDA-approved in 1990 under the brand name Geref® for the diagnosis and treatment of growth hormone deficiency in children . Its approval was discontinued in 2008 for commercial reasons, not due to safety or efficacy concerns . It is currently available as a compounded medication for off-label use in anti-aging and wellness medicine .
Important Notice:
FOR RESEARCH USE ONLY. NOT FOR HUMAN USE, THERAPEUTIC, OR DIAGNOSTIC APPLICATIONS outside approved clinical settings.
Select Option & Quantity
Key Benefits
- High purity research compound (>98%)
- Third-party tested and verified
- Lyophilized for maximum stability
- Certificate of analysis available
